Table 3.
Time-varying HR estimatesa from a fixed-effects NMA of RFS/DFS (p1 = 0, p2 = −1, scale, shape ×1) in patients with resected stage II–IV melanoma
| Treatment | Time points | |||
|---|---|---|---|---|
| 12 months | 24 months | 36 months | 48 months | |
| NIVO vs. OBS/PBO | 0.58 (0.43–0.77) | 0.51 (0.33–0.80) | 0.46 (0.26–0.86) | 0.43 (0.21–0.91) |
| NIVO vs. DAB+TRAM | 1.02 (0.71–1.47) | 0.46 (0.27–0.78) | 0.28 (0.14–0.59) | 0.20 (0.08–0.49) |
| NIVO vs. PEM | 1.19 (0.81–1.76) | 1.06 (0.56–2.05) | 0.96 (0.40–2.29) | 0.88 (0.30–2.51) |
| NIVO vs. IPI (10 mg/kg) | 0.69 (0.55–0.86) | 0.66 (0.46–0.96) | 0.65 (0.40–1.07) | 0.64 (0.35–1.17) |
| NIVO vs. IPI (3 mg/kg) | 0.75 (0.54–1.04) | 0.93 (0.58–1.48) | 1.06 (0.57–2.01) | 1.16 (0.54–2.55) |
| NIVO vs. CHEM | 0.63 (0.44–0.89) | 0.53 (0.32–0.86) | 0.47 (0.24–0.91) | 0.42 (0.19–0.95) |
| NIVO vs. IFN | 0.64 (0.48–0.86) | 0.55 (0.36–0.88) | 0.49 (0.27–0.93) | 0.46 (0.22–0.97) |
aThe value in each cell represents the hazard ratio (95% credible interval) for the comparison of the treatments; bolded values are statistically significant at the 0.05 significance level
CHEM other chemotherapy, DAB dabrafenib, DFS disease-free survival, HR hazard ratio, IFN interferon, IPI ipilimumab, NIVO nivolumab, NMA network meta-analysis, OBS observation, PBO placebo, PEM pembrolizumab, RFS recurrence-free survival, TRAM trametinib